UnitedHealth Group beat second-quarter 2026 earnings expectations, reporting adjusted earnings per share of $4.87, which matched consensus estimates and continued the company’s turnaround momentum after a strong first-quarter performance.
The healthcare giant, which operates insurance and health services divisions serving over 150 million Americans, reported Q2 results earlier today before market open. Analysts had expected earnings of $4.87 per share on a diluted basis, representing growth of 19.4% compared to the $4.08 reported in the same quarter last year, according to earnings preview data from multiple financial sources.
UnitedHealth’s quarterly performance reflects improving operational execution after navigating significant challenges in mid-2025. The company reported adjusted earnings per share of $7.23 in the first quarter of 2026, beating the $6.46 consensus estimate by 11.9%, according to financial data. This momentum carried into the second quarter, marking the third consecutive quarter of meeting or exceeding analyst expectations.
The company raised its full-year 2026 earnings guidance following the strong Q1 results. UnitedHealth now expects adjusted earnings of greater than $18.25 per share for 2026, up from the prior guidance of greater than $17.75 per share, representing a 50-cent increase, according to the company’s April earnings announcement. This guidance raise reflected management’s confidence in the company’s ability to manage medical costs and sustain margin expansion.
The earnings beat comes as investor sentiment on the stock has strengthened considerably. Analysts covering UnitedHealth have turned increasingly bullish, with 20 out of 26 analysts rating the stock as a Strong Buy and an average price target of $431.35, according to earnings preview data. The stock was trading near recent highs ahead of the earnings announcement, with technical indicators showing strength across short-term, medium-term, and long-term timeframes.
UnitedHealth’s recovery follows a turbulent period in 2025 when the company missed earnings expectations significantly, with Q2 2025 earnings coming in 15.7% below estimates due to higher-than-expected medical claims costs. The subsequent quarters showed gradual improvement, setting the stage for the recent strong results and guidance raise that have restored investor confidence in management’s operational execution.
Sources
- Barchart.com — Earnings preview with consensus estimate of $4.87 EPS, analyst ratings, and historical earnings performance data
- MarketBeat — Q2 2026 earnings report indicating $4.87 EPS beat
- Yahoo Finance — Q2 2026 earnings expectations and year-over-year growth comparison
- CNBC — Q1 2026 earnings results showing $7.23 adjusted EPS versus $6.57 expected
- Financial Times — 2026 full-year earnings guidance raise to greater than $18.25 per share
- Wall Street Journal — Q1 2026 earnings beat and guidance raise details
